R&D Biotech strategy and nanomedicine: the pharmaphorum podcast For episode 5 of the pharmaphorum podcast Dominic Tyer met Blueberry Therapeutics’ CEO Dr John Ridden at The Wellcome Coll
Events Partner Content NANO.IL.2018, the leading international nanotechnology confe... NANO.IL.2018 conference & exhibition
Views & Analysis Nanomedicine: delivering on its promise? The nanomedicines market is worth billions. Tarun Pandotra reviews developments in the sector.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
